Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxOther Accumulated ExpensesPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

VitaNova Life Sciences (YJGJ) Cash & Equivalents (2017 - 2026)

VitaNova Life Sciences (YJGJ) has disclosed Cash & Equivalents for 8 consecutive years, with $1.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash & Equivalents rose 465.22% year-over-year to $1.3 million, compared with a TTM value of $1.3 million through Oct 2025, up 465.22%, and an annual FY2025 reading of $782810.0, up 32.0% over the prior year.
  • Cash & Equivalents was $1.3 million for Q4 2025 at VitaNova Life Sciences, up from $1.0 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $1.3 million in Q4 2025 and bottomed at $8728.0 in Q2 2023.
  • Average Cash & Equivalents over 5 years is $362483.5, with a median of $141635.0 recorded in 2024.
  • The sharpest move saw Cash & Equivalents crashed 70.18% in 2023, then skyrocketed 7240.02% in 2024.
  • Year by year, Cash & Equivalents stood at $31693.0 in 2021, then rose by 14.19% to $36190.0 in 2022, then plummeted by 75.88% to $8728.0 in 2023, then surged by 2452.65% to $222795.0 in 2024, then soared by 465.22% to $1.3 million in 2025.
  • Business Quant data shows Cash & Equivalents for YJGJ at $1.3 million in Q4 2025, $1.0 million in Q3 2025, and $782810.0 in Q2 2025.